Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of July 2023, with a specific report date of July 17, 2023. The filing addresses the company's regulatory status regarding its listing on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of regulatory compliance rather than a financial results announcement.
Material Changes
The primary material change reported is the resolution of a prior listing deficiency. Evogene has regained compliance with Nasdaq Listing Rule 5550(a)(2), which mandates a minimum bid price of $1.00 per share. This compliance was achieved after the closing bid price of Evogene's ordinary shares remained at $1.00 or greater for 13 consecutive business days. Consequently, Nasdaq has closed the prior bid price deficiency matter.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No new risks, contingencies, or unusual items are disclosed in this specific document beyond the resolution of the listing compliance issue.
Key Facts for Investor Verification
- Evogene has officially regained compliance with Nasdaq Listing Rule 5550(a)(2).
- The compliance determination was based on a closing bid price of $1.00 or more for 13 consecutive business days.
- The prior bid price deficiency matter is now considered closed by Nasdaq.
- This filing does not contain updated financial performance data.